Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

April 22, 2026

New York Stock Exchange US Consumer Staples Tobacco earnings 72 min

What were the key takeaways from Philip Morris International Inc.'s April 22, 2026 earnings call?

In Q1 2026, Philip Morris International Inc. (PM:US) reported net revenues of over $10 billion, reflecting a 9% increase year-over-year, and adjusted diluted earnings per share (EPS) of $1.96, up 16%. The strong performance was driven by robust growth in the international smoke-free segment, particularly from IQOS and ZYN, despite challenges in the U.S. combustible market. Management maintained its full-year guidance for organic net revenue growth of 5% to 7% and adjusted diluted EPS growth of 7.5% to 9.5%, indicating confidence in ongoing momentum despite macroeconomic uncertainties.

What topics did Philip Morris International Inc. cover?

  • Strong Smoke-Free Growth: The international smoke-free business delivered double-digit volume growth, with IQOS showing an impressive 11.9% volume increase and 15.8% net revenue growth. Management stated, "The excellent organic performance of smoke-free was the clear standout," highlighting its importance to overall growth.
  • Resilience of Combustible Business: The combustible segment achieved low single-digit organic growth, with management noting, "This was especially remarkable considering cigarette volume declines were at the more negative end of our expectations." This reflects the enduring pricing power of the Marlboro brand.
  • Guidance Reaffirmed: Management reaffirmed its full-year guidance for organic net revenue growth of 5% to 7% and adjusted diluted EPS growth of 7.5% to 9.5%. They stated, "We continue to expect strong global smoke-free growth for the full year, supported by high single-digit volume progression and normalizing U.S. comparison."
  • Impact of U.S. Market Dynamics: Management acknowledged challenges in the U.S. market, particularly for ZYN, stating, "As anticipated, segment financial performance was challenging due to the specific combination of impact this quarter." However, they expect performance to improve later in the year.
  • Pricing Power and Margin Expansion: Adjusted gross profit grew by 10% to $6.9 billion, with gross margin expansion of 70 basis points. Management attributed this to strong pricing and operating leverage, stating, "We achieved this through strong pricing, operating leverage and the continued benefit of smoke-free mix."

What were Philip Morris International Inc.'s April 22, 2026 results?

  • Net Revenue: $10B (+9% YoY)
  • Adjusted EPS: $1.96 (+16% YoY)
  • Adjusted Gross Profit: $6.9B (+10% YoY)
  • Adjusted Diluted EPS Guidance: $8.36 to $8.51 (plus 10.9% to 12.9% growth)

Philip Morris International's strong Q1 results highlight the effectiveness of its smoke-free transformation strategy, particularly with IQOS and ZYN. The reaffirmed guidance suggests confidence in sustained growth, though challenges in the U.S. market warrant close monitoring. Investors should watch for the impact of upcoming product launches and regulatory developments on future performance.

Earnings Call Speaker Segments

Emmanuel Babeau

executive
#1

We got off to a powerful start this year, thanks to exceptional expansion in our smoke-free segment abroad and really firm pricing, which produced remarkable gains even though the prior-year comparison was especially tough for both the U.S. and combustible products. Earnings came in above what we had projected, generating adjusted operating income growth of 10% and adjusted diluted EPS growth of 16%, arriving at $1.96. Our international smoke-free unit turned in an extraordinary showing, with volumes up by double digits, organic revenue rising in the mid-teens, and organic gross profit climbing in the high teens — roughly 30% when measured in dollars. IQOS drove this, posting adjusted in-market sales growth near 11%, while ZYN added further multi-category gains and captured the estimated joint number one spot across Europe according to Nielsen. Our combustible segment posted solid financial results, matching our midterm model with organic revenue up in the low single digits and organic gross profit up in the low to mid single digits. That stands out all the more given that cigarette volume declines landed at the worse end of what we had anticipated, after a prior-year stretch of volume gains stemming from several temporary factors; it speaks to the lasting pricing strength of our portfolio, Marlboro above all, together with disciplined cost control. Within the U.S., ZYN offtake volumes rose 10% even as competition intensified. As expected, segment financials proved difficult because of this quarter's particular mix of pressures, among them heavier investment and a comparison against Q1 2025, a period with virtually no price promotion and a substantial inventory rebuild once supply constraints eased. We also noted last quarter that channel inventory remained excessive at the close of 2025, and that situation mostly corrected itself during Q1, which weighed on shipments. We keep investing to fuel future growth and anticipate U.S. results improving steadily across 2026 as we get ready to introduce ZYN Innovations and year-over-year comparisons settle down, particularly during the back half. Broadly speaking, although the worldwide economic picture remains unpredictable, our robust Q1 financials highlight our momentum and bolster our confidence that we will once again deliver best-in-class growth. Now let's go through our Q1 results more closely, beginning with the headline financials. Net revenues came in above $10 billion, up 9% as reported and up 2.7% organically, beating our forecast of roughly flat results. Strength in category portfolio more than made up for the Q1-specific U.S. and combustible challenges I referenced earlier. Adjusted gross profit climbed 10% to $6.9 billion, driven by 3.8% organic growth and 70 basis points of organic gross margin expansion. We got there through firm pricing, operating leverage and the ongoing advantage of smoke-free mix, partially offset by the expected U.S. hit from those same factors and partially offset by greater reinvestment in growth; adjusted operating income likewise topped our guidance, rising 10% to $4.2 billion alongside organic growth of nearly 1%. On an adjusted basis, diluted EPS rose a strong 16%, reaching $1.96. That figure includes an $0.18 benefit from currency, helped by a favorable transactional effect in Q1 along with the broadly softer U.S. dollar. Our effective tax rate came in a touch ahead of what we had anticipated, and it was more advantageous this quarter than the full-year rate we had projected. International results were excellent this quarter, with gross profit and OCI each up roughly 10% on an organic basis and about 16% in dollar terms. We managed that while investing heavily behind our smoke-free portfolio. Smoke-free stood out clearly thanks to its superb organic performance: volumes up 11.9%, net revenue up 15.8%, and gross profit up 19.4%, which pushed gross margin up 210 basis points to 70%. The main forces behind that were IQOS continuing to build broadband momentum, plus a growing contribution from ZYN and VEEV. Across PMI as a whole, our global smoke-free operation posted very solid organic net revenue growth of 5.3% and organic gross profit growth of 3.9%, and notwithstanding what is happening in the U.S., we still anticipate robust global smoke-free growth for the full year, backed by high single-digit volume improvement and a normalizing U.S. comparison. In international combustibles, volumes fell 5.1%, yet organic net revenues rose 1% and gross profit climbed 3.9%, as strong pricing and disciplined cost management more than offset headwinds from volume mix. Organic gross margin widened by 190 basis points, which highlights how resilient this business is. Now to volumes: total shipments were down 1.9%, against our forecast of broadly stable for the full year. Smoke-free shipments rose a very healthy 9.1% year over year, matching our full-year target of high single-digit growth; the primary driver was an 11% rise in HTU to 41.3 billion units, which included a modest net phasing benefit of about 0.5 billion units spread across several markets. On top of that, e-vapor's stellar 95% growth largely offset a 16% drop in oral smoke-free volume, reflecting notably the U.S. shipment and inventory headwinds we discussed earlier as well as timing dynamics in the Nordics. Total smoke-free product in-market sales volume was up 11%. Cigarette volumes fell at the high end of what we expected and exceeded the 2.3% decline seen across the international industry. Several dynamics explain this, among them lapping exceptional volume growth of 1.1% in Q1 2025, which had included inventory replacement in a handful of markets like Indonesia, Russia, Italy and Spain. Beyond that, a difficult economic backdrop has fueled more illicit consumption in some markets, while excise hikes in certain countries — most notably Mexico in January — produced a substantial industry decline. Going forward, we see volume declines easing in the quarters ahead, and we still project a cigarette volume decline of about 3% for the full year. That figure incorporates a negative industry impact in India after new excise rates took effect in Q1. If we examine what powered our top line in Q1, robust pricing along with favorable mix from deliberate smoke-free moves outweighed the drag on volume and mix coming out of the U.S. and combustible. The single biggest lift came from pricing, which contributed plus 5 points. Underneath that, combustible pricing posted another solid quarter at plus 8.5%, while international smoke repricing reached plus 2.9%, with IQOS leading the way and counterbalancing heavier routine promotional activity in the U.S. versus the unusually minimal level seen in Q1 2025. International smoke-free mix likewise delivered a sizable favorable contribution of plus 2.7 points; that gain was partially countered by a 1.8 point effect from the U.S. tied to the unusual confluence of factors already described. Currency contributed an additional plus 6.4 points, bringing reported net revenue growth to plus 9.1% for the quarter. Taken as a whole, the makeup of Q1 growth tracks closely with the structural engines of pricing strength and smoke-free mix that we have consistently delivered in recent years. This highlights how sustainable and consistent our growth model is. Turning next to adjusted operating income margins, these rose plus 40 basis points, climbing past 41%.

Emmanuel Babeau

executive
#2

One key element here was a favorable currency effect, and that let us lift margin even with more money going back into future growth, plus some unfavorable timing and comparison dynamics. The gross margin gain added 70 basis points, coming from the drivers I described earlier, with just a minor effect from disruption and higher costs tied to the Middle East conflict. On SG&A, we stayed on plan, putting more into the control program, scale and innovation, in international markets and the U.S. alike. Q2 should bring another sizable year-over-year investment step-up, but we see that easing in H2, and for the full year SG&A should grow organically at or under net revenue growth. Currency gave us a solid tailwind of 110 basis points, helped by an easy comparison against transactional losses a year ago. All told, even though this quarter carried the year's weakest expected organic growth, we keep funding our smoke-free portfolio, backed by efficient back office and manufacturing cost management, together with roughly $150 million of gross cost efficiency booked in Q1. We stay on course for organic margin expansion across the full year in 2026. Now to our global smoke-free business: we posted IMS volume growth of about 11% in Q1, roughly 3 percentage points better than the industry smoke-free product growth rate in the market and category where PMI operates. That shows our capacity to take over 70% of industry growth there, against a share of roughly 60%, powered by the strength and scale of our multi-category portfolio; we keep working to build on those strengths with 3 geographies, bringing in one more category to hit 55 multi-category markets and 2 additional markets for smoke-free products, for 108 in total. That covers the ZYN rollout in Portugal and Kenya plus VEEV in Egypt. Inside smoke-free International, IQOS had another robust quarter, with adjusted in-market sales up 10.9%. That mirrors very solid, broad-based momentum across markets and regions, Europe and Japan among them. Adjusted IMS volumes beyond those 2 geographies rose 19%, with strong growth in Korea, Malaysia, Indonesia, GCC Mexico and outstanding early results in Taiwan. As of now, after launching there in Q4 '25, Taiwan stands as our best major IQOS launch market ever, with a national exit offtake share of nearly 6% in March. That equals about 70% of industry < > volume and almost doubles our combined Taiwanese cigarette and HTU market share over the last 6 months. Global Travel Retail likewise kept up double-digit HTU growth, with only a modest Middle East impact. Q1 adjusted in-market sales carried a consumer pantry loading benefit of about 0.5 billion in Japan, ahead of the April 1 excise-driven price increase. Strip out that temporary effect and growth was still strong at 9.4%. What's key here is that IQOS keeps getting more profitable, even as we keep putting money behind the brand, and that's thanks to a rising pricing contribution, ongoing gains from scale, and productivity gains on both consumables and devices. Innovation is still a crucial driver when it comes to acceptance and retention among legal-age nicotine consumers, and it widens the choices available across test profile and price points. In the quarter, we kept rolling out innovations on our flagship < > consumables, and we also saw excellent traction from extending our mainstream price DELIA and the tobacco-free variant, < >. We're also making headway on the rollout of our alternative it not burn technology bonds by IQOS: after encouraging results from the first launches in key cities in Italy, we started a national rollout in the quarter. A large share of these consumers are deeply established traditional cigarette users, which fits squarely with our mission of offering better alternatives that appeal to every cohort of adult smokers. IQOS's strength keeps showing up in the sustained offtake share gains across key cities, which serve as a lead indicator for national success; among the impressive Q1 milestones: Tokyo went past 40% share for the first time, Global Travel Retail came in above 20%, Munich was over 16%, and Madrid exceeded 10%. Back to Taiwan. One standout was Taipei, where IQOS share got above 7% in its second quarter after launch and finished March at nearly 8%. More market and SSP volume data is available in the appendix to these slides. IQOS is a core engine of our international smoke-free business, while ZYN and VEEV reinforce and round out our multi-category strategy, with great momentum and major global opportunities. ZYN kept delivering fast growth. Modern oral shipment volumes rose plus 7% on a comparable basis, or plus 42% if you exclude the more mature Nordic market; on that latter scope, which is where the biggest opportunity sits. We estimate offtake volumes were up well over 50% and that we gained share in a dynamic category; that notably takes in strong results in markets including the U.K., Pakistan, Poland and Mexico. Volumes fell in the Nordics, mainly because of timing dynamics. We keep broadening our portfolio to serve legal aged smokers who want to switch, by offering a wide spectrum of adult appropriate flavor and strength. That includes rolling out our lower strength offering, the XO 1.5 milligrams, across a large majority of our 58 international ZYN markets, which drives a significant improvement in first experienced nicotine acceptance among adult nicotine consumers. In e-vapor, VEEV maintained its remarkable momentum in the quarter, reinforcing its position as the fastest-growing international < > brand among major players. I'm pleased to share that VEEV became the joint #1 close pot brand in Europe in Q4 '25, as estimated by Nielsen < > across 19 markets, surpassing long-established players. For the first time, equivalent unit shipments in a quarter went past 1 billion, while IMS volumes nearly doubled. That was powered by remarkable expansion in Italy, Romania, Germany, the U.K., France, Spain and Indonesia. With our reach now extending across 49 markets, this swift volume increase and an improving positive margin profile show how much more valuable this is becoming inside our multi-category portfolio. Europe makes that particularly evident, since VEEV played a major role in helping deliver shipment volume growth of plus 12% for IQOS, ZYN and VEEV during the quarter, which more than made up for the ZYN situation in the Nordics I discussed earlier, with plus 31% growth in other places. IQOS adjusted IMS volume rose by plus 5.4%, with really strong results throughout the region, even with continuing disruption in Ukraine and the early effects of the EU characterizing flavor ban being implemented in Poland. If you leave out markets where the bank took CapEx in January 2025, like Poland and Hungary, adjusted IMS volumes were up roughly plus 8%, as the brand keeps up its powerful momentum. Double-digit growth carried on in Italy once the flavor ban, which took effect in mid-2024, had been annualized. Spain, Germany, Greece, Romania, Serbia, Bulgaria and the Netherlands are among the other markets posting notable strong growth. For the rest of the year, we anticipate continued solid IQOS growth in Europe. In Japan, the heat-not-burn category kept expanding robustly, hitting roughly 53% of total industry offtake volume in Q1. IQOS adjusted IMS volumes climbed plus 10.4%, or approximately plus 6% when consumer pantry loading is excluded.

Emmanuel Babeau

executive
#3

This strong pace of expansion shows the brand still has plenty of momentum, and it produced a notable gain in adjusted market share, hitting a record 34.9%. Even though competition in the category stays fierce, IQOS accounted for nearly 70% of industry heat-not-burn volumes, which speaks to how powerful the combination of product, brand, and commercial reach has become; on the shipment side, Japan HTUs rose just marginally versus the same period a year earlier, a period that carried a timing benefit of roughly 1 billion units. As noted during our last quarter, shipment figures and adjusted IMS can diverge over the course of a year because of the excise adjustments in April and October. In fact, for Q2 we anticipate that adjusted IMS growth will show the unwinding of consumer pantry loading along with the price hikes that began on April 1. It is too soon to say how consumers are initially responding, yet our confidence in the expansion of IQOS and of the broader category in Japan across the years ahead is unchanged. Turning to the U.S., ZYN remains the leader in nicotine pouches, with offtake up 10% in Q1 according to Nielsen estimates; that result was achieved even with a competitive landscape in which our portfolio still does not cover every one of the most vibrant strength and flavor segments. Although offtake volume grew, Q1 shipment fell to 155 million cans, a consequence of the inventory situation discussed last quarter, which I will quickly review now. Given roughly 40 million cans of inventory rebuild in Q1 '25, the underlying shipment base tied to consumer offtake came to about 160 million cans. That means the underlying volume this quarter was roughly 10% larger, at approximately 175 million cans. As we signaled at our full year results in February, we put surplus inventory in the downstream supply chain at the end of 2025 at around 25 million cans. That surplus, as expected, was mostly worked off during the first quarter of 2026, which pushed shipment volumes below consumer offtake. Some quarter-to-quarter shipment variability is normal in any market, but our base assumption is that ZYN shipments ought to broadly match offtake growth in future quarters against the estimated underlying 2025 basis we gave in February of approximately 180 million cans in Q2, 205 million cans and 200 million cans in Q4. What matters more than inventory swings, though, is the direction of offtake growth for both ZYN and the category. With that in mind, in addition to brand building and commercial execution, we are intensely focused on innovation and are getting our manufacturing and commercial operations ready for new product launches in the months ahead. This adds to our investment in U.S. manufacturing capacity, with our Aurora facility steadily ramping up initial operations. That leads me to our main priorities for generating growth and value from leading this promising category. First, we keep investing in the ZYN brand and in the long-term growth of our U.S. business; that covers marketing, distribution, and commercial activation, plus regular promotional activity, which was unusually light in H1 '25. And then the second thing is we're still operating within a complicated, fast-moving regulatory landscape, and that has consequences for how quickly innovation can happen and for how quickly someone who legally smokes can move to a better alternative. The science makes it plain that nicotine pouches represent a far superior option for those adult consumers who would otherwise be smoking. We've also taken note of the data that came out recently from the National Youth Tobacco Survey, which indicated that use by minors in this category held steady or edged down slightly, staying at low levels under 2%, even as the category grew strongly. Getting authorization for < > through the FDA's nicotine pouch pilot program is still something we're prioritizing. Our application is still undergoing active scientific review. And as part of that process, our dialogue with the FDA has been ongoing. The goal the FDA has for the pilot program is to boost efficiency and make the review process smoother. And although it has run longer than the target. The science behind our application is solid, and we're optimistic that we can bring this product to consumers in the months ahead. On top of that, we've filed a number of ZYN submissions with the FDA that sit at different points in the regulatory process, and we're getting ready to introduce more innovation to the market, also in the months ahead. Turning to IQOS, we're happy that the FDA has now granted reauthorization to the earlier version as a modified risk tobacco product. We remain in contact with the FDA regarding authorization for IQOS ILUMA, so that American smokers can get access to the largest and most successful smoke-free product worldwide in achieving a complete switch away from cigarettes. All in all, we look ahead with confidence toward future growth in our U.S. business. Last, shifting to combustible, which yet again showed how resilient our net revenue and gross profit growth model is, even with a significant Q1-specific volume headwind that we anticipate will ease considerably over the rest of the year. Very strong pricing, up 8.5%, served as the main driver, with noteworthy contributions from Turkey, Indonesia and Mexico. Though we expect some moderation, especially during the second half of the year, because of timing and comparison effects, we now project a full year variance exceeding 6%. International combustible gross profit rose by 3.9% organically and 9.8% in dollar terms, even after a strong showing the year before, which keeps us nicely on track for yet another year of robust delivery. Our cigarette category share fell 0.6 points to 24.8%. A strong showing in Egypt was offset by market mix and declines in Indonesia and Russia, mostly reflecting pricing dynamics along with the ongoing share recovery in Turkey. Marlboro once again highlighted the strength of its premium brand equity, hitting a record first quarter share of 10.7%, which is up 0.4 points year-on-year. Our aim is still to keep category share broadly steady as time goes on, with an explicit emphasis on driving value via growth in both the top and bottom lines, while giving active backing to the ongoing expansion of smoke-free products; that leads me into what we expect for 2026. In the first quarter, the Middle East conflict had a minor effect on our business, hitting shipments into global travel retail and specific regional markets for combustibles as well as HTUs. We've seen higher energy prices and some energy supply disruption across a number of markets, yet at this point that hasn't turned into any noticeable change in how consumers behave. How long this lasts and what it may ultimately do remain unclear, and judging the wider consequences for consumers or for global costs is hard. We've built in certain rises in transport, energy and other input costs. And we'll keep watching developments closely so we can gauge the medium- to long-term effects across the key variables. Recognizing that uncertainty, and after a solid start to the year in Q1, we are reaffirming the currency-neutral growth guidance we gave in February; we still anticipate broadly stable shipment volumes, organic net revenue growth of plus 5% to plus 7%; and organic operating income growth of plus 7% to plus 9% along with currency-neutral adjusted diluted earnings per share growth of plus 7.5% to plus 9.5%.

Emmanuel Babeau

executive
#4

Even though currency markets are moving around a lot right now, at today's rates we're projecting a $0.25 currency tailwind, which brings our adjusted diluted EPS guidance to $8.36–$8.51, or growth of 10.9% to 12.9% in dollar terms. Looking at the second quarter, we anticipate our international business will keep performing strongly and that growth will improve sequentially, with HTU shipment volume between 40 billion and 42 billion, while HTU adjusted IMS growth will be slower because of the near-term effect of excise-related pricing in Japan, alongside a low single-digit decline in cigarette shipment volume. We're expecting organic net revenue growth in the mid-single digits and solid operating income improvement, even with yet another quarter of heavy commercial investment. We're forecasting adjusted diluted EPS of $2.02–$2.07, which includes a higher effective tax rate and a $0.02 favorable currency variance at current rates; that quarter also lines up with the release of our value report 2025, which gives a thorough financial and nonfinancial picture of our strategy, governance and priorities for creating sustainable long-term value. With our 2025 road map now complete, we're calling attention to what we've achieved over the last 5 years on our most material sustainability priorities. Among the key accomplishments: our smoke-free business kept expanding, underage access prevention in indirect retail was further strengthened, we reached carbon neutrality in our direct operation, we eliminated systemic child labor from our tobacco supply chain, and we moved forward on effective anti-littering efforts. We also launched our value plan 2030, a focused, business-driven framework built on 6 priorities: Consumer, circularity, our workforce, workers in our value chain, climate and nature. As the report lays out, our approach to sustainable value is completely woven into our business strategy, helping grow our more transformation and bolstering long-term resilience, competitiveness and value creation. Anyone curious about how we're carrying out our transformation should really take a look at the report. I'll wrap up today's presentation with a handful of key takeaways. Our strong, resilient first quarter performance mirrors the structural growth fundamentals of our business model. Three powerful drivers keep underpinning our results: strong pricing, favorable mix from the ongoing shift to smoke-free product, and volume growth led by IQOS, ZYN and VEEV. Even as we keep investing in future growth, these drivers are profit accretive and, along with pricing power and cost management, strengthen our confidence in our midterm growth targets. The operating environment is still complex and marked by macroeconomic uncertainty, but we believe we're well positioned to navigate external headwinds. Our smoke-free transformation keeps building momentum, backed by remarkable cash generation and a strong balance sheet. Last, we stay firmly committed to our progressive dividend policy and to returning value to shareholders as our transformation delivers sustainable long-term growth. We look ahead to the rest of 2026 with confidence. Thank you, and we're now very happy to take your questions. <<operator_script>> Our first question will come from the line of Eric Serotta from Morgan Stanley.

Eric Serotta

analyst
#5

Let's begin with smoke-free, or international smoke-free — that gross margin figure above 70% is really impressive. In the past you've mentioned that you're still in the early stages of optimizing the supply chain and truly reaping gross margin gains across international IQOS. When you consider < >, how big a priority does that remain, given margins are already very high and there's plenty of growth runway ahead? Then my other question concerns U.S. ZYN. Your price gaps have definitely widened back out, and they're not that far from where < > flagged them last September as being wider than you'd prefer.

Jacek Olczak

executive
#6

Thanks, Eric. Now, regarding the international smoke-free margin — yes, you've got that right, we continue to improve. I'd call it a mix of factors. Most importantly, as you pointed out, IQOS has kept delivering strong results; we've implemented price increases in quite a few markets; for smoke-free we're at roughly 3% on pricing, and of course IQOS accounts for the biggest share of that. Let me be clear — that isn't our number one priority, since we've often pointed out that with IQOS and our smoke-free lineup worldwide, margins come in higher than they do on combustible products, which is a great thing. On top of that, when you measure in dollars, we're well over two times higher per unit, both for revenue and for gross profit. So driving volume as high as possible is certainly a major goal. Still, as we expand the portfolio, we're creating a highly appealing brand, with IQOS standing out sharply — but just look at what we're doing with VEEV; those are shaping up more like brands such as Viva in international. At this point, those two brands are far smaller in scale compared with IQOS, and we're still focused on making them profitable. That said, IQOS is a major contributor here. I'd say we're doing everything we can to get the most profit out of each unit, but we haven't forgotten that what really matters in this case is pushing volume as high as possible, since that adds very strongly to our overall profitability. Turning to your other question about ZYN in the U.S., I'd say that by and large, the price premium relative to competitors is unchanged from a few months ago. Keep in mind this isn't a fixed number we can lock in, since rivals keep adjusting what they charge too, and around the world we've witnessed quite a bit of aggressive behavior on price from a commercial standpoint. At its core, ZYN sits at the top of this category. Think about the sheer strength our brand carries today next to all the other players in the space — how unique we are, how much power the brand holds — and that counts for something. Being number one means we'll remain the pricier choice on the shelf, and continuing that way is our plan. Obviously, we must monitor on an ongoing basis whether that higher price point still makes sense compared with what competitors are doing. Ultimately, although we won't abandon our guiding principle — building a top brand with an attractive premium and profitable position — we must make sure we offer the optimal price for it and fine-tune every lever, pricing included, to reach that goal. Obviously, I can't go deeper into pricing specifics. It's an extremely delicate topic. Still, in the end, just remember this: our aim is to remain the number one brand, a premium brand, standing somewhat apart from the competition, and we will adjust the levers to get there.

Bonnie Herzog

analyst
#7

I’d perhaps like to ask a follow-up about ZYN in the U.S. You mentioned that you anticipate performance getting better as the year goes on. So I’d like to understand more clearly what’s behind that confidence. And I’m interested to hear how much you’re prepared to keep giving up near-term profitability in order to push volume growth? And then lastly, we’re all aware you’ve been hurt by the FDA not putting nic pouch applications through expedited review. So I’m curious whether you’d think about simply launching some of the innovation you’ve referred to without getting approval.

Jacek Olczak

executive
#8

Yes. Of course, Bonnie; glad to address that. I’ll restate what I’ve been saying about what our aim with ZYN in the U.S. really is. But I’m definitely glad to go into more detail on why we anticipate a far more favorable trend during the latter half of the year. To begin, let me take a few seconds on Q2. Keep in mind that a year ago, we still had some market reloading during Q2, far more so than in Q1. That, though, means we lack a completely clean underlying performance to compare against for Q2. Next, you’ll recall that a year ago in Q2, there was, once again, hardly any promotional activity, so we had an unusually elevated revenue per can. Consequently, during Q2, we’ll be up against what is ZYN’s growth in the market. And here, this year, I mean, each week, you can follow Nielsen and that provides some indications. I won’t claim it’s scientifically exact, but it offers some picture of how ZYN is performing. And you’ll see that effect on invoicing and revenue < > Then in the year’s second priority, that’s when we reach a normalizing of the comparison base regarding revenue per can. We ought to have, too, in terms of shipment, something that is more underlying as a reference point. There will be, naturally, in Q3, last year’s one-off free can operation that has to be factored in. But as you’re aware, it also weighed negatively on our financial performance in Q3. So that’s a negative factor that won’t be affecting things. And after that, as we’ve stated, we expect innovation to arrive in the months ahead. I can’t say precisely when it will arrive or when it will take effect; but naturally, when we say we expect to be able to introduce innovation in the months ahead, that means we expect innovation to have a positive effect on our latter half of the year. We’ll say precisely when this will contribute. So when you put all of those pieces together — the capacity we anticipate needing to bring online alongside innovation so we can capitalize on a dynamic category, plus the tough year-over-year comparisons we faced during H1 on both shipments and revenue per can — everything there turns more favorable across the back half of the year. That, I believe, is what accounts for the momentum we're projecting. As for innovation in general and the launches we have planned, I won't go into detail; you can surely understand how highly sensitive that subject is, and we won't be disclosing anything there. Still, I think our determination to deliver innovation is unmistakable, and that's exactly what a leader such as ours ought to do.

Bonnie Herzog

analyst
#9

That's reasonable. I value that extra context. If I can follow up, one thing on IQOS: your first-quarter numbers beat what you were expecting, and a major factor was IQOS's momentum. Emmanuel, you mentioned this, but I'm hoping for more detail about what drove that momentum and what specifically outperformed. I also wanted to check whether first quarter IQOS had any timing advantages that could later unwind. Last, regarding IQOS profitability, your margins keep widening, and as you said, you keep spending; so I'd like to grasp what will mainly fuel profit growth going forward — is it price, efficiency gains, or both?

Jacek Olczak

executive
#10

< > The largest factor in our overall results is IQOS. I don't believe anywhere in the world's smoke category has anything comparable to IQOS, this multibillion-dollar brand, well above $10 billion. It's a one-of-a-kind offering. This brand has steadily held roughly 75% of the category, which, when discussing novation, is truly exceptional. Consumers see a very obvious point of difference. And of course, now that we're speaking of a $10 billion plus brand, it brings a distinctive brand franchise and a distinctive effect; so ultimately, the outcome stems from IQOS being a superb product that satisfies smokers' needs and expectations and clearly sets itself apart from every rival product. That's what stands behind the iQOS success. If I were to pick 1 market to show that — and I find it fairly striking this quarter — it's Italy returning to robust double-digit expansion. Fine, Italy was plainly shaken by the flavor ban and needed a few months to adapt; yet we're back to that < > growth in Italy, we're hitting very high share above 20% in certain key cities, and we're bringing innovation; so, as I discussed innovation a few minutes ago, a top brand must innovate. And I'd say nobody rivals IQOS when it comes to innovation. Terra, what we're doing with DELIA, what we're doing with < >. We're introducing bonds, and bonds is making a very good stride in Italy, quite fascinating to observe. I believe that's the DNA of a leading powerful brand, and that truly is what stands behind IQOS's success; on margin improvement, it's price. So we're raising price — obviously it's quite different, as I explained, quite a different story compared with combustible, but we're raising price on IQOS and on iQOS consumable across a number of markets. Naturally, we continue focusing on making the supply chain more efficient and lowering what the electronics inside the device cost; through our supply chain, we're also addressing productivity so that the expense tied to consumables keeps getting better, steadily and without interruption. That's yet another factor truly driving why IQOS has succeeded. I could honestly talk for a great number of minutes about what makes IQOS a success. Taiwan could have come up as an example. Obviously, reaching a 6% share of the market there within just a few months is rather striking, with 8% in Taipei by March; and the brand hadn't even been launched there. So I believe it simply demonstrated that the brand already has a powerful reputation even in places where IQOS isn't sold. I'd call that a tribute to what IQOS represents now.

Pallav Mittal

analyst
#11

I'll go through these one at a time. Starting with nicotine pouches in the U.S.: could you give us some clarity on how excise taxes work there? A handful of states have put forward proposals to raise excise taxes. Then earlier this month, according to < > data, pricing across the whole category seemed to speed up quite a bit. So is anything shifting when it comes to taxes? And what's the industry doing in response to those increases and the discussions around them?

Jacek Olczak

executive
#12

Glad to address that. Obviously, like everyone else, we're picking up talk in a few states — not all of them, just some — about levying an excise duty on nicotine pouches. Let's stay careful here. I'd feel far more at ease giving my view once things actually occur, since speculating about proposals is hard to do. We aren't arguing that nicotine products ought to be completely untaxed as a blanket principle. I'm not referring to — just the U.S. in this case; our view is that within the risk continuum, taxation ought to differ quite sharply between small free product and combustible. Nicotine pouches, sitting of course at a very favorable spot along that continuum, deserve especially favorable treatment through a low excise duty level; so to us, that ought to be how regulators behave globally, and it ought to let smokers and consumers move toward the better product with greater purchasing power. Here in the U.S., I'd add that this point holds too, since you've got a regulator — the FDA — that is plainly, in my view, stating these products are far better than combustible cigarettes and is working to speed up a number of PMTAs because it believes consumers ought to be able to choose between products, perhaps to boost the odds of switching away from combustible cigarettes; and my view is that imposing heavy taxes in that setting works against the FDA's intention and vision. So that, I think, would be a PT, and it's clear we're not heading in the right direction.

Pallav Mittal

analyst
#13

Okay. Turning back to nicotine pouches in the U.S. one more time — if I look at how Zen's volume has been trending, and I use the Nielsen figures as my dosing basis, then pretty soon that could become a flat volume number, or maybe even a shrinking one, provided ZYN Ultra still has dealers out there and I project the current pattern forward. And clearly, the PMDA timeline isn't something you control. So what gives you the confidence that Zen Ultra, when it does hit the market, will get growth accelerating again — is there a specific market that's the source of that confidence? And then, on the innovations you're calling out: I'm not asking you to say what exactly that is. Is the timing for those innovations and for getting those products onto the market once again tied to the FDA and PMDA processes? Or is that something you control?

Jacek Olczak

executive
#14

Yes. First, on this topic, regarding innovation, naturally we adhere to the processes; so, again, it's obvious when this would arrive, but a process exists in the U.S., and we are complying with it very diligently—I'm stating what's evident this year. On the ZYN volume trajectory, so yes, we're in the range of roughly 5%, 6% growth. I'm referring to the most recent week. We'll see what, if anything, is going to be speculated about. But clearly, our expectation is that ZYN Ultra is going to arrive with a proposal. Our view is that this offering is excellent, and the accompanying launch plan will target the segments of the U.S. nicotine pouch category that are showing the most vigorous growth right now. As a result, we anticipate that ZYN Ultra will restore some fresh momentum to the Zen brand over the next several months. That is what we expect.

Pallav Mittal

analyst
#15

Okay, and I want to touch on IQOS for a moment. When we look at European growth of roughly 5.5%, does that come in a little below your expectations? In the past, Europe's growth ran in the high single digits to low double digits. What steps will you take to lift that 5% to 6% growth back up to a high single-digit figure?

Jacek Olczak

executive
#16

Not at all. European growth is genuinely strong, since once you set aside the market that recently expanded because of the flavor ban, you land at about 8% growth. In absolute terms, naturally, the figure would be greater since the base is larger, yet it aligns closely with the pattern from the prior quarter. So, setting those two markets aside — and Poland is a major one, along with some turbulence in Ukraine. I mean, disruption in Ukraine continues, but during the quarter there were several impacts. Everywhere else, the market remains highly dynamic, and naturally we anticipate that Poland and Hungary will work through this turbulence and move past it over the next few quarters, just as happened in other European countries.

Andrei Andon-Ionita

analyst
#17

First off, regarding heated tobacco. Can you give us some detail about the initial patterns you're picking up on in Japan following the excise tax hike that took effect on April 1? Then second, on combustibles, the release noted that in Germany you've observed a noticeable drop in volume. Is that because of market share? Or is the industry as a whole experiencing a deceleration in early 2026? And last, maybe this is more of a technical one; we saw corporate expenses post a big decrease versus the prior year. Can you explain what's driving that, and do you think it will continue in Q2 and after?

Jacek Olczak

executive
#18

Glad to address that. So regarding Japan, well, if you caught the remark back then, naturally, we aren't offering any observations; it was merely 14 days ago, or slightly over that, since the price hike took effect in Japan. It's premature to make a call. The one thing I will say is that nothing in what we've observed during the initial days would, in my view, run counter to what I said regarding our assurance about the continuation of — over the long run — robust expansion of the category and IQOS's success in Japan. But regardless, let's consider what the disruption in Q2 will be. I believe we laid out the reversal we anticipate. And within a few weeks and in a couple of months, we'll be far better positioned to speak about the pattern in Japan following this excise duty rise. In combustibles in Germany, I believe there was both — there's a market that's somewhat soft; yet the industry too is somewhat soft, and you get some decrease. So a mix of the two, I'd say, with the German consumer likely feeling somewhat squeezed. And concerning the corporate expense, it's mostly technical. It's currency losses and transactional losses in the 125 since that's where transactional losses get placed and it's a comparison effect, so it appears improved; that's truly the reason; however, it's a Q1 occurrence, to be clear. That doesn't imply that for the remainder of the year, we aren't anticipating things to be far more aligned versus last year on corporate expenses.

Matt Smith

analyst
#19

I'd like to circle back to a few points you made about IQOS by bonds and its nationwide rollout in Italy. Could you share what kind of incrementality you're observing from that product compared to trade down, plus what the profitability looks like today for IQOS by bonds relative to IQOS, and how you see that changing? Also, what scale is required for that change and for profitability?

Jacek Olczak

executive
#20

Sure, I'm glad to address that. So as I said, bonds by IQOS represents a really positive step forward, consistent with what market leaders ought to deliver. And the initial move in Italy along with several other markets appears to have validated that there's clearly something appealing here, and that we could persuade certain people who previously had not been making the switch to now move to a superior option with bonds. Regarding profitability, as one would anticipate, the key objective is that it must match combustible at a minimum. Should we be able to achieve more, we'll explore that; but for sure, it won't arrive with a margin below that of our combustible business.

Gerald Pascarelli

analyst
#21

Now, another question about what's happening with IQOS stock levels in Japan. I believe you've already made the 2Q outlook quite clear. However, when we think about a second price hike tied to excise tax that's coming later in the year, did consumer stockpiling account for all of that inventory movement in the first quarter, and are there any safeguards to prevent wholesalers from building up their stock, plus how do you view the possible effect that could have across the third and fourth quarters and the back half of the year?

Jacek Olczak

executive
#22

Well, we'll find out — it's too soon to discuss October. There may be comparable elements, which would naturally hinge on whatever each company decides regarding raising prices. And I definitely won't say anything at this point. So let's see — a similar effect isn't out of the question, though I can't say for certain yet. Let me revisit this topic later in the year, once we have clearer visibility.

Analyst

analyst
#23

If it's okay, I have a couple of things to ask. Both relate to SI in America, or you could say the nicotine pouch segment. The first is about the segment itself. When I look at recent scanner data on U.S. nicotine pouch volume growth, it seems like things have softened a bit over the past three to six months. What do you see as the main reasons for that — that's my first question. And the second, coming back to ZYN Ultra, I'm not asking about timing, but I'd like to know your view on potential regulatory concerns around stronger nicotine levels and a broad range of flavors, particularly when it comes to the category attracting people who don't use nicotine?

Jacek Olczak

executive
#24

Yes. I'll start with that point. That piece you're probably mentioning was largely guesswork. My view is we've been quite clear that strong scientific evidence exists showing these items are far superior to cigarettes. According to that NYTS research, there's been no rise — actually a small decline — in youth use within the U.S., so it's difficult to identify anything that's shifted regarding the FDA's stance. Furthermore, they granted authorization to a different product. If I recall correctly, that happened in December, so fairly recently, and that one contains a greater amount of nicotine than what ZYN currently offers. If flavor or stronger nicotine were truly a problem for them, I really don't think they'd have granted this approval just a handful of months back. <> The percentage shouldn't carry too much weight either, since a high percentage brings gross profit along with a high rate of growth. Sure, that percentage is clearly coming down, but the absolute figure for nicotine pouches keeps climbing regardless — at the same pace, or perhaps even quicker. So we shouldn't overlook the genuine growth underneath. And after that, when new consumers possibly enter the category, there might be some uncertainty, at least early on. Frequently, when someone begins using nicotine pouches, they're already using multiple products. What does a typical new user consume each day? It's possible that one factor behind the trend easing just a bit over recent months is that certain recent adopters currently arrive with a reduced ADC. Honestly though, apart from that, I can't really point to anything else.

Analyst

analyst
#25

Could I slip in a quick 1, I suppose — we've got this high single-digit figure.

Executive

executive
#26

Sorry, we're really short on time now, and we only want to fit in 1 additional analyst after you, though we'll get back to you afterward.

Analyst

analyst
#27

I’d like to add one more thing, picking up where the previous question left off, specifically regarding U.S. ZYN and how nicotine pouch consumers behave, since as this segment keeps expanding, it has also become more developed. So I suppose what I’m wondering is whether we’ve reached a stage where you can point to signs that users who consume more per capita are moving up from 3 to 6-milligram pouches to stronger nicotine options such as 9 milligrams, possibly more quickly than has happened before. Naturally, I’m asking that with ZYN Ultra in mind, and whether merely having a higher-nicotine product available to compete against would be sufficient on its own to bring about a renewed pickup in volumes.

Executive

executive
#28

We appreciate your participation today; that brings our call to a close. If anything further comes up, please reach out to the Investor Relations team. Thanks once more, and enjoy the rest of your day.

Jacek Olczak

executive
#29

Thank you. Speak to you soon.

Operator

operator
#30

Appreciate everyone joining us for today's call. That brings the program to a close. You're welcome to disconnect at this point. Have a wonderful day, everybody.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.